Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1995 1
2012 2
2014 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration.
Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S, Colin S, Ferry A, Conduzorgues JP, Hadri A, Cursiefen C, Udaondo P, Viaud E, Thorin E, Chemtob S. Cloutier F, et al. Among authors: conduzorgues jp. Invest Ophthalmol Vis Sci. 2012 Mar 9;53(3):1195-203. doi: 10.1167/iovs.11-9064. Invest Ophthalmol Vis Sci. 2012. PMID: 22323484
The antiangiogenic insulin receptor substrate-1 antisense oligonucleotide aganirsen impairs AU-rich mRNA stability by reducing 14-3-3β-tristetraprolin protein complex, reducing inflammation and psoriatic lesion size in patients.
Colin S, Darné B, Kadi A, Ferry A, Favier M, Lesaffre C, Conduzorgues JP, Al-Mahmood S, Doss N. Colin S, et al. Among authors: conduzorgues jp. J Pharmacol Exp Ther. 2014 Apr;349(1):107-17. doi: 10.1124/jpet.113.209346. Epub 2014 Feb 6. J Pharmacol Exp Ther. 2014. PMID: 24504098 Clinical Trial.
[The industrial future small batches].
Conduzorgues JP. Conduzorgues JP. Presse Med. 2012 May;41 Suppl 1:S55-6. doi: 10.1016/j.lpm.2012.02.019. Epub 2012 Apr 4. Presse Med. 2012. PMID: 22480860 French. No abstract available.